Newsletter
Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more

JAMA Editor’s Summary

Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more

May 09, 2017 edition of the weekly JAMA Editors' Summary
May 9, 2017

Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more

May 09, 2017 edition of the weekly JAMA Editors’ Summary

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp